Drugs /

r-chop regimen

Back to Drugs List

Overview

NCI Definition [1]:
An immunochemotherapy regimen consisting of rituximab, cyclophosphamide, hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride), vincristine (Oncovin) and prednisone used to treat both indolent and aggressive forms of non-Hodgkin lymphoma

Clinical Trials

View Clinical Trials for r-chop regimen

R-chop regimen has been investigated in 16 clinical trials, of which 16 are open and 0 are closed. Of the trials investigating r-chop regimen, 5 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (5 open), 1 is phase 2/phase 3 (1 open), and 4 are phase 3 (4 open).

BCL2 Fusion, MYC Fusion, and BCL6 Fusion are the most frequent biomarker inclusion criteria for r-chop regimen clinical trials.

Diffuse large B-cell lymphoma, diffuse large B-cell lymphoma, not otherwise specified, and double-hit lymphoma are the most common diseases being investigated in r-chop regimen clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating R-Chop Regimen
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating r-chop regimen and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
cyclophosphamide/doxorubicin/prednisone/rituximab/vincristine, ctx/dox/moab idec-c2b8/pred/vcr, rituxan/chop
NCIT ID [1]:
C9760

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.